Literature DB >> 19732389

Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae.

Rie Isozumi1, Hiroyuki Yoshimine, Miyuki Morozumi, Kimiko Ubukata, Koya Ariyoshi.   

Abstract

A 28-year-old woman with community-acquired pneumonia was treated with sulbactam/ampicillin and clarithromycin, but failed to show any improvement after 4 days. The antibiotic regimen was changed to pazufloxacin and rapid clinical improvement was seen. Mycoplasma pneumoniae was identified as the causative agent, and adenine (A) to guanine (G) mutation at position 2063 in domain V of the 23S rRNA was noted in the isolate. The minimum inhibitory concentration of macrolide antibiotics, including clarithromycin, of this isolate was greatly elevated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732389     DOI: 10.1111/j.1440-1843.2009.01619.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

Review 1.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 2.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

3.  Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance.

Authors:  Soo Jin Yoo; Hyo-Bin Kim; Sang-Ho Choi; Sang-Oh Lee; Sung-Han Kim; Sang-Bum Hong; Heungsup Sung; Mi-Na Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

4.  Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia.

Authors:  Naoyuki Miyashita; Yasuhiro Kawai; Hiroto Akaike; Kazunobu Ouchi; Toshikiyo Hayashi; Takeyuki Kurihara; Niro Okimoto
Journal:  BMC Infect Dis       Date:  2012-05-31       Impact factor: 3.090

5.  Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010.

Authors:  Diana Averbuch; Carlos Hidalgo-Grass; Allon E Moses; Dan Engelhard; Ran Nir-Paz
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

6.  Macrolide resistance of Mycoplasma pneumoniae and its detection rate by real-time PCR in primary and tertiary care hospitals.

Authors:  Young Uh; Joo Hee Hong; Ki Jin Oh; Hyun Mi Cho; Soon Deok Park; Juwon Kim; Kap Jun Yoon
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

Review 7.  Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuyoshi Kenri
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

8.  Characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumoniae.

Authors:  Haruki Komatsu; Tomoyuki Tsunoda; Ayano Inui; Tsuyoshi Sogo; Tomoo Fujisawa
Journal:  Braz J Infect Dis       Date:  2014-01-03       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.